Table 3 Subgroup analysis of the prognostic value of CRP for PFS in patients with ovarian cancer

Total

7

1790

Fixed

1.55 (1.30–1.84)

< 0.001

9.3

0.358

Geographical region

 Asia

6

1672

Fixed

1.61 (1.35–1.93)

< 0.001

0

0.644

 Non-Asia

1

118

–

0.84 (0.42–1.67)

0.618

–

–

Sample size

 < 150

2

169

Random

1.65 (0.83–3.27)

0.152

65.0

0.057

 ≥ 150

5

1621

Fixed

1.53 (1.26–1.86)

< 0.001

0

0.841

FIGO stage

 I–IV

6

1477

Fixed

1.56 (1.31–1.87)

< 0.001

22.7

0.264

 III–IV/IV

1

313

–

1.36 (0.70–2.66)

0.369

–

–

Treatment

 Surgery + chemotherapy

6

1477

Fixed

1.56 (1.31–1.87)

< 0.001

22.7

0.264

 NAC + surgery/chemotherapy/surgery

1

313

–

1.36 (0.70–2.66)

0.369

–

–

CRP cutoff value (mg/L)

 < 10

4

1431

Fixed

1.62 (1.29–2.03)

< 0.001

0

0.708

 ≥ 10

3

359

Random

1.46 (0.85–2.51)

0.167

58.8

0.088

Cutoff determination

 ROC curve

6

1739

Fixed

1.51 (1.27–1.80)

< 0.001

0

0.470

 Median/mean value

1

51

–

2.91 (1.20–7.01)

0.018

–

–

Survival analysis

 Univariate

3

554

Fixed

1.56 (1.20–2.04)

0.001

7.5

0.339

 Multivariate

4

1236

Fixed

1.54 (1.23–1.93)

< 0.001

32.6

0.217